CN100343258C - 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物 - Google Patents

新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物 Download PDF

Info

Publication number: CN100343258C
Authority: CN; China
Prior art keywords: carbon atoms; halogen; atoms; group; alkenyl
Prior art date: 2001-04-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CNB028133102A

Other languages

English (en)

Chinese (zh)

Other versions

CN1522258A (zh

Inventor

A·施托勒

D·E·比雷尔

陈元伟

范冬平

B·哈特

M·K·莫纳汉

W·J·斯科特

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Corp

Original Assignee

Bayer Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-30

Filing date

2002-04-29

Publication date

2007-10-17

2002-04-29 Application filed by Bayer Corp filed Critical Bayer Corp

2004-08-18 Publication of CN1522258A publication Critical patent/CN1522258A/zh

2007-10-17 Application granted granted Critical

2007-10-17 Publication of CN100343258C publication Critical patent/CN100343258C/zh

2022-04-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

CNB028133102A 2001-04-30 2002-04-29 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物 Expired - Fee Related CN100343258C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28762901P	2001-04-30	2001-04-30
US60/287,629		2001-04-30

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA2007101410179A Division CN101100472A (zh)	2001-04-30	2002-04-29	4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用

Publications (2)

Publication Number	Publication Date
CN1522258A CN1522258A (zh)	2004-08-18
CN100343258C true CN100343258C (zh)	2007-10-17

Family

ID=23103719

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CNB028133102A Expired - Fee Related CN100343258C (zh)	2001-04-30	2002-04-29	新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
CNA2007101410179A Pending CN101100472A (zh)	2001-04-30	2002-04-29	4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CNA2007101410179A Pending CN101100472A (zh)	2001-04-30	2002-04-29	4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用

Country Status (6)

Country	Link
US (1)	US6849638B2 (2)
EP (1)	EP1401840A4 (2)
JP (2)	JP2005503345A (2)
CN (2)	CN100343258C (2)
MX (1)	MXPA03009925A (2)
WO (1)	WO2002088138A1 (2)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2217956B1 (es) *	2003-01-23	2006-04-01	Almirall Prodesfarma, S.A.	Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
NZ542236A (en) *	2003-03-31	2008-05-30	Predix Pharmaceuticals Holding	New piperidinylamino-thieno[2,3-d]pyrimidine compounds
ES2280040T3 (es)	2003-07-24	2007-09-01	Bayer Pharmaceuticals Corporation	Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos.
US8207172B2 (en) *	2004-08-20	2012-06-26	Bayer Intellectual Property Gmbh	Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders
ES2343196T3 (es) *	2004-10-27	2010-07-26	Bayer Schering Pharma Aktiengesellschaft	Pirimidotienoindazoles capaces de inhibir tirosina quinasas del factor de crecimiento epidermico.
CA2655799A1 (en) *	2005-06-22	2006-12-28	Develogen Aktiengesellschaft	Thienopyrimidines for pharmaceutical compositions
WO2007067946A2 (en) *	2005-12-07	2007-06-14	The Regents Of The University Of California	Diagnosis and treatment of chronic lymphocytic leukemia (cll)
CA2651898A1 (en) *	2006-04-07	2007-10-18	Develogen Aktiengesellschaft	Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en)	2006-07-10	2008-02-20	DeveloGen Aktiengesellschaft	Pyrrolopyrimidines for pharmaceutical compositions
US8637528B2 (en) *	2007-03-27	2014-01-28	Omeros Corporation	Use of PDE7 inhibitors for the treatment of movement disorders
JP5580192B2 (ja) *	2007-03-27	2014-08-27	オメロスコーポレーション	運動障害の処置のためのｐｄｅ７インヒビターの使用
US7982035B2 (en)	2007-08-27	2011-07-19	Duquesne University Of The Holy Spirit	Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
CA2699349C (en)	2007-09-14	2016-04-19	Bayer Schering Pharma Aktiengesellschaft	Substituted tricyclic heterocyclic compounds for use as egfr inhibitors
ATE537175T1 (de) *	2007-10-19	2011-12-15	Boehringer Ingelheim Int	Neue piperazino-dihydrothienopyrimidin-derivate
EP2205609B1 (de)	2007-10-19	2017-03-29	Boehringer Ingelheim International GmbH	Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
MX2010004026A (es)	2007-10-19	2010-04-30	Boehringer Ingelheim Int	Piperidino-dihidrotienopirimidinas sustituidas.
JP2011500621A (ja) *	2007-10-19	2011-01-06	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規フェニル置換ピペラジノ−ジヒドロチエノピリミジン
EP2257554A1 (en) *	2008-02-19	2010-12-08	Vichem Chemie Kutató KFT	Tricyclic benzoý4,5¨thieno-ý2,3-d¨pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
UY32072A (es)	2008-08-26	2010-03-26	Boehringer Ingelheim Int	Tienopirimidinas para composiciones farmacéuticas
CN102984941B (zh) *	2009-09-04	2016-08-17	密执安大学评议会	用于治疗白血病的组合物和方法
UY33241A (es)	2010-02-26	2011-09-30	Boehringer Ingelheim Int	?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
JP5575274B2 (ja)	2010-02-26	2014-08-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物のためのｍｎｋｌ／ｍｎｋ２阻害活性を有する４−［シクロアルキルオキシ（ヘテロ）アリールアミノ］チエノ「２，３−ｄ］ピリミジン
MX2012009851A (es)	2010-02-26	2012-09-12	Boehringer Ingelheim Int	Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmaceuticas.
EP2595993B1 (en) *	2010-07-23	2018-04-18	President and Fellows of Harvard College	Tricyclic proteasome activity enhancing compounds
CN106038567A (zh)	2010-11-08	2016-10-26	奥默罗斯公司	使用pde7抑制剂治疗成瘾和冲动控制障碍
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN102532159B (zh) *	2010-11-12	2015-02-11	姚雪彪	动点马达蛋白CENP-E小分子抑制剂Syntelin
WO2012097013A1 (en) *	2011-01-10	2012-07-19	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
US9802954B2 (en)	2011-08-24	2017-10-31	Boehringer Ingelheim International Gmbh	Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en)	2011-08-24	2013-03-07	Boehringer Ingelheim International Gmbh	Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
JP6126131B2 (ja) *	2012-01-10	2017-05-10	ニンバスアイリス，インコーポレイテッド	Ｉｒａｋ阻害剤およびその使用
AU2013202373B2 (en) *	2012-01-25	2016-04-14	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
EP2806875B1 (en)	2012-01-25	2017-07-19	Proteostasis Therapeutics, Inc.	Proteasome activity modulating compounds
CA2873967A1 (en) *	2012-05-21	2013-11-28	Bayer Pharma Aktiengesellschaft	Substituted benzothienopyrimidines
HK1206723A1 (en)	2012-05-21	2016-01-15	Bayer Pharma Aktiengesellschaft	Thienopyrimidines
WO2014011902A1 (en)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
WO2014011906A2 (en)	2012-07-11	2014-01-16	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
TW201412740A (zh)	2012-09-20	2014-04-01	Bayer Pharma AG	經取代之吡咯并嘧啶胺基苯并噻唑酮
CA2890911A1 (en)	2013-01-10	2014-07-17	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
US8778365B1 (en)	2013-01-31	2014-07-15	Merz Pharmaceuticals, Llc	Topical compositions and methods for making and using same
JP2016514087A (ja)	2013-02-01	2016-05-19	バイエル・ファルマ・アクティエンゲゼルシャフト	置換チエノピリミジンおよびその薬学的使用
EP2961403A4 (en)	2013-03-01	2016-11-30	Zalicus Pharmaceuticals Ltd	HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
WO2014135480A1 (en)	2013-03-06	2014-09-12	Bayer Pharma Aktiengesellschaft	Substituted thiazolopyrimidines
CN106232122A (zh)	2013-09-27	2016-12-14	林伯士艾瑞斯公司	Irak抑制剂和其用途
TW201605867A (zh) *	2013-11-20	2016-02-16	拜耳製藥公司	噻吩并嘧啶
EP3110799A4 (en) *	2014-02-27	2017-10-11	Epirus Biopharmaceuticals, Inc.	Heterocyclic inhibitors of the sodium channel
JP2017519737A (ja) *	2014-05-26	2017-07-20	バイエル・ファルマ・アクティエンゲゼルシャフト	置換テトラヒドロピリドチエノピリミジン
USRE49687E1 (en)	2014-09-09	2023-10-10	The Regents Of The University Of Michigan	Thienopyrimidine and thienopyridine compounds and methods of use thereof
HK1246593A1 (zh)	2015-06-04	2018-09-14	Kura Oncology, Inc.	用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh)	2015-06-04	2020-09-01	美商庫拉腫瘤技術股份有限公司	用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
PH12018501955B1 (en)	2016-03-16	2024-01-24	Kura Oncology Inc	Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl)	2016-03-16	2023-07-17	Kura Oncology, Inc.	Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
WO2018175746A1 (en)	2017-03-24	2018-09-27	Kura Oncology, Inc.	Methods for treating hematological malignancies and ewing's sarcoma
CN107158003B (zh) *	2017-05-19	2020-10-30	中山大学	4n杂环化合物的衍生物在制备用于治疗自身免疫疾病的药物中的应用
WO2018226976A1 (en)	2017-06-08	2018-12-13	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en)	2017-09-20	2021-09-08	Kura Oncology, Inc.	SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
WO2022192224A1 (en)	2021-03-09	2022-09-15	Fmc Corporation	Bicyclic amides for controlling invertebrate pests
US20260048059A1 (en)	2022-08-18	2026-02-19	Klaus Wirth	Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc
WO2023097341A2 (en)	2023-03-20	2023-06-01	Fmc Corporation	Bicyclic amides and esters for controlling invertebrate pests

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4146716A (en) *	1975-11-28	1979-03-27	Imperial Chemical Industries Limited	Thienopyrimidines
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JPH01313480A (ja) *	1988-06-14	1989-12-18	Nippon Soda Co Ltd	ピリミジン誘導体、その製造方法及び農園芸用殺菌剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3823151A (en)	1968-08-02	1974-07-09	Ciba Geigy Corp	4,5,6,7-tetrahydrothieno(2,3-d)pyridines
DE1937459A1 (de)	1968-08-02	1970-02-05	Ciba Geigy	Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung
US3681351A (en)	1970-04-15	1972-08-01	Ian Wellings	CERTAIN 5,6,7,8-TETRAHYDRO-5,8-ETHANO-PYRIDINO{8 2,3-b{9 -THIENO{8 5,4-d{9 PYRIMIDINES
ES381459A1 (es) *	1970-07-04	1972-11-16	Lab Made S A Patronato Invest	Procedimiento para la obtencion de piperazinas n'-disus-ti-tuidas.
US3670079A (en) *	1970-10-06	1972-06-13	Merck & Co Inc	Anabolic agents
US4997936A (en) *	1977-10-19	1991-03-05	Merck & Co., Inc.	2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4456464A (en) *	1982-05-19	1984-06-26	Zoecon Corporation	Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control
US4526608A (en) *	1982-07-14	1985-07-02	Zoecon Corporation	Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use
US4590282A (en) *	1984-09-24	1986-05-20	Sandoz Ltd.	Pest control agents
US4845088A (en) *	1985-07-01	1989-07-04	Merck & Co., Inc.	Tetrazolyl derivatives of beta-lactams useful as elastase inhibitors
US4933339A (en) *	1985-08-21	1990-06-12	Rohm And Haas Company	(2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity
DD245667A1 (de) *	1985-09-20	1987-05-13	Univ Halle Wittenberg	Verfahren zur herstellung von 4-(alkoxycarbonylalkyl-bzw.-arylamino)-thieno 2,3-d pyrimidinen
CA1328333C (en) *	1988-03-04	1994-04-05	Quirico Branca	Amino acid derivatives
US4879309A (en) *	1988-09-27	1989-11-07	Schering Corporation	Mercapto-acylamino acids as antihypertensives
AU651337B2 (en)	1990-03-30	1994-07-21	Dowelanco	Thienopyrimidine derivatives
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US5356903A (en) *	1993-04-22	1994-10-18	Sterling Winthrop Inc.	1-cyclopropyl-4-pyridyl-quinolines
JPH07126255A (ja) *	1993-09-10	1995-05-16	Eisai Co Ltd	キナゾリン系化合物
US6316439B1 (en) *	1993-10-15	2001-11-13	Aventis Pharamaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
DE19632423A1 (de) *	1996-08-12	1998-02-19	Merck Patent Gmbh	Thienopyrimidine
DE19644228A1 (de) *	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
JP3919272B2 (ja) *	1996-12-18	2007-05-23	エーザイ・アール・アンド・ディー・マネジメント株式会社	キナゾリン系化合物
RU2116309C1 (ru) *	1997-02-13	1998-07-27	Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского	4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
DE19752952A1 (de) *	1997-11-28	1999-06-02	Merck Patent Gmbh	Thienopyrimidine
WO1999043674A1 (en) *	1998-02-27	1999-09-02	Kyowa Hakko Kogyo Co., Ltd.	Remedies for erectile dysfunction
WO1999046267A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
EP1067123B1 (en) *	1998-03-31	2011-01-19	Kyowa Hakko Kirin Co., Ltd.	Nitrogenous heterocyclic compounds
CZ27399A3 (cs) *	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CN1346358A (zh)	1999-03-30	2002-04-24	日本曹达株式会社	噻吩并嘧啶化合物及其盐和制备方法
PL354784A1 (en) *	1999-09-30	2004-02-23	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
DE10042997A1 (de) *	2000-09-01	2002-03-14	Merck Patent Gmbh	Thienopyrimidine
DE10064994A1 (de) *	2000-12-23	2002-07-04	Merck Patent Gmbh	Sulfamidothienopyrimidine

2002
- 2002-04-29 MX MXPA03009925A patent/MXPA03009925A/es active IP Right Grant
- 2002-04-29 EP EP02734103A patent/EP1401840A4/en not_active Withdrawn
- 2002-04-29 JP JP2002585436A patent/JP2005503345A/ja not_active Withdrawn
- 2002-04-29 CN CNB028133102A patent/CN100343258C/zh not_active Expired - Fee Related
- 2002-04-29 CN CNA2007101410179A patent/CN101100472A/zh active Pending
- 2002-04-29 WO PCT/US2002/013630 patent/WO2002088138A1/en not_active Ceased
- 2002-04-29 US US10/136,575 patent/US6849638B2/en not_active Expired - Fee Related
2010
- 2010-02-15 JP JP2010030397A patent/JP2010155847A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4146716A (en) *	1975-11-28	1979-03-27	Imperial Chemical Industries Limited	Thienopyrimidines
US4196207A (en) *	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JPH01313480A (ja) *	1988-06-14	1989-12-18	Nippon Soda Co Ltd	ピリミジン誘導体、その製造方法及び農園芸用殺菌剤

Also Published As

Publication number	Publication date
MXPA03009925A (es)	2004-06-30
EP1401840A1 (en)	2004-03-31
JP2010155847A (ja)	2010-07-15
US20030119829A1 (en)	2003-06-26
WO2002088138A1 (en)	2002-11-07
CN101100472A (zh)	2008-01-09
CN1522258A (zh)	2004-08-18
EP1401840A4 (en)	2007-05-16
US6849638B2 (en)	2005-02-01
JP2005503345A (ja)	2005-02-03

Legal Events

Date	Code	Title	Description
2004-08-18	C06	Publication
2004-08-18	PB01	Publication
2004-10-27	C10	Entry into substantive examination
2004-10-27	SE01	Entry into force of request for substantive examination
2007-10-17	C14	Grant of patent or utility model
2007-10-17	GR01	Patent grant
2010-09-22	C17	Cessation of patent right
2010-09-22	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20071017

Publication	Publication Date	Title
CN100343258C (zh)	2007-10-17	新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
CN1294135C (zh)	2007-01-10	作为蛋白激酶抑制剂的吡咯并嘧啶
CN100343255C (zh)	2007-10-17	吡唑并[1,5－a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
CN1171889C (zh)	2004-10-20	作为p38蛋白激酶的抑制剂的杂烷基氨基－取代的双环氮杂环类化合物
CN1188389C (zh)	2005-02-09	用于治疗由细胞因子引起的疾病的苯甲酰胺衍生物
CN1051311C (zh)	2000-04-12	N－杂芳基－n'－苯脲衍生物及其生产和应用
CN1592624A (zh)	2005-03-09	被取代的三唑并嘧啶类化合物作为抗癌药
HK1045687A1 (zh)	2002-12-06	作為抗腫瘤劑的4，5，6，7-四氫吲唑衍生物
CN101048412A (zh)	2007-10-03	哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
CN1761671A (zh)	2006-04-19	用作PDE7抑制剂的4－氨基噻吩并[2,3－d]嘧啶－6－甲腈衍生物
CN1714092A (zh)	2005-12-28	作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
CN1138780C (zh)	2004-02-18	噻吩并嘧啶类
CN1606444A (zh)	2005-04-13	人磷脂酰肌醇3－激酶δ抑制剂
CN1551881A (zh)	2004-12-01	新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
CN1742010A (zh)	2006-03-01	新的化学化合物
CN1688582A (zh)	2005-10-26	稠合吡咯－嘧啶衍生物
CN1218471A (zh)	1999-06-02	咔啉衍生物
CN1161334A (zh)	1997-10-08	新的取代胍衍生物，其制备方法和其药物用途)
CN1649581A (zh)	2005-08-03	取代的3－氨基－噻吩并[2,3－b]吡啶－2－羧酸酰胺化合物及其制备方法和用途
CN1056879A (zh)	1991-12-11	吡咯衍生物及其制备方法
CN1809564A (zh)	2006-07-26	用作pde10抑制剂的吡咯并二氢异喹啉
CN1055182A (zh)	1991-10-09	N-(吡咯并《2，3-d》嘧啶-3-基酰基)-谷氨酸衍生物
CN1300291A (zh)	2001-06-20	蛋白质酪氨酸磷酸酶(ptp酶)的调节物
CN1395578A (zh)	2003-02-05	吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
CN1127486C (zh)	2003-11-12	二氮杂萘衍生物磷酸二酯酶4抑制剂